Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1996-12

AUTHORS

I. Raßmann, H. Schrödel, T. Schilling, M. Zucchetti, A. Kaeser-Fröhlich, J. Rastetter, A. -R. Hanauske

ABSTRACT

We have conducted a clinical and pharmacokinetic trial of the novel podophyllotoxin derivative NK611 administered orally for 21 consecutive days. The treatment was repeated every 35 days. Eighteen patients were included into the study, all of whom were eligible. Due to early progression of tumor disease in two patients, 16 patients were evaluable for toxicity [7 female, 9 male, median age 64 years (range: 44 to 73)]. Dose escalation steps were 5 mg/day [105 mg per cycle (pc)], 10 mg/day (210 mg pc), 12.5 mg/day (265 mg pc) and 15 mg/day (315 mg pc). A total of 37 courses was administered. Toxicity was evaluated using NCI-CTC criteria. Granulocytopenia was the main hematologic toxicity. Other hematologic toxicities were sporadic. Non-hematologic toxicities were mild and consisted of grade 1 nausea and grade 2 alopecia. Pharmacokinetic analyses were performed in six patients each treated with 10 mg/day and 12.5 mg per day, and in one patient treated with 15 mg/day. Using a two-compartment model, t1/2 alpha ranged from 0.47 to 1.54 h and t1/2 beta from 2.0-11.6 h. Mean values for Cmax and AUC were 1.47 +/- 0.331 microgram/ml and 13.67 +/- 3.81 micrograms/ml.h. No objective tumor responses were observed. However, one patient with metastatic breast cancer had stable disease for twelve months. We conclude that the Maximum Tolerated Dose of NK611 administered daily for 21 consecutive days is 12.5 mg/day. The Dose-Limiting Toxicity is granulocytopenia. The recommended dose for further clinical Phase II studies is 10 mg/day. More... »

PAGES

379-386

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00180814

DOI

http://dx.doi.org/10.1007/bf00180814

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048548766

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9157073


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukopenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Podophyllotoxin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Rechts der Isar Hospital", 
          "id": "https://www.grid.ac/institutes/grid.15474.33", 
          "name": [
            "Division of Hematology and Oncology, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ra\u00dfmann", 
        "givenName": "I.", 
        "id": "sg:person.0764624435.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764624435.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rechts der Isar Hospital", 
          "id": "https://www.grid.ac/institutes/grid.15474.33", 
          "name": [
            "Division of Hematology and Oncology, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schr\u00f6del", 
        "givenName": "H.", 
        "id": "sg:person.01032737635.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032737635.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rechts der Isar Hospital", 
          "id": "https://www.grid.ac/institutes/grid.15474.33", 
          "name": [
            "Division of Hematology and Oncology, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schilling", 
        "givenName": "T.", 
        "id": "sg:person.0636044662.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636044662.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mario Negri Institute for Pharmacological Research", 
          "id": "https://www.grid.ac/institutes/grid.4527.4", 
          "name": [
            "Oncological Department, Istituto \u201cMario Negri\u201d, Milano, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zucchetti", 
        "givenName": "M.", 
        "id": "sg:person.0720105551.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720105551.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evonik (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420017.0", 
          "name": [
            "Asta Medica GmbH, Frankfurt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaeser-Fr\u00f6hlich", 
        "givenName": "A.", 
        "id": "sg:person.01215301435.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215301435.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rechts der Isar Hospital", 
          "id": "https://www.grid.ac/institutes/grid.15474.33", 
          "name": [
            "Division of Hematology and Oncology, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rastetter", 
        "givenName": "J.", 
        "id": "sg:person.016016223701.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016016223701.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rechts der Isar Hospital", 
          "id": "https://www.grid.ac/institutes/grid.15474.33", 
          "name": [
            "Division of Hematology and Oncology, Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanauske", 
        "givenName": "A. -R.", 
        "id": "sg:person.01114224637.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114224637.79"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/0959-8049(95)00245-e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016202311"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bmc.1130070207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029012041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bmc.1130070207", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029012041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-4347(93)e0453-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033050826"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0305-7372(93)90046-t", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039091038"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0378-4347(94)00481-j", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047214758"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800050524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047341901", 
          "https://doi.org/10.1007/s002800050524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-468x(83)90006-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048030318"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0010-468x(83)90006-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048030318"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a059180", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082437870"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a058789", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082692174"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1996-12", 
    "datePublishedReg": "1996-12-01", 
    "description": "We have conducted a clinical and pharmacokinetic trial of the novel podophyllotoxin derivative NK611 administered orally for 21 consecutive days. The treatment was repeated every 35 days. Eighteen patients were included into the study, all of whom were eligible. Due to early progression of tumor disease in two patients, 16 patients were evaluable for toxicity [7 female, 9 male, median age 64 years (range: 44 to 73)]. Dose escalation steps were 5 mg/day [105 mg per cycle (pc)], 10 mg/day (210 mg pc), 12.5 mg/day (265 mg pc) and 15 mg/day (315 mg pc). A total of 37 courses was administered. Toxicity was evaluated using NCI-CTC criteria. Granulocytopenia was the main hematologic toxicity. Other hematologic toxicities were sporadic. Non-hematologic toxicities were mild and consisted of grade 1 nausea and grade 2 alopecia. Pharmacokinetic analyses were performed in six patients each treated with 10 mg/day and 12.5 mg per day, and in one patient treated with 15 mg/day. Using a two-compartment model, t1/2 alpha ranged from 0.47 to 1.54 h and t1/2 beta from 2.0-11.6 h. Mean values for Cmax and AUC were 1.47 +/- 0.331 microgram/ml and 13.67 +/- 3.81 micrograms/ml.h. No objective tumor responses were observed. However, one patient with metastatic breast cancer had stable disease for twelve months. We conclude that the Maximum Tolerated Dose of NK611 administered daily for 21 consecutive days is 12.5 mg/day. The Dose-Limiting Toxicity is granulocytopenia. The recommended dose for further clinical Phase II studies is 10 mg/day.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00180814", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days", 
    "pagination": "379-386", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00180814"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e7472c7cc3d909221bbfe475fd1c97af62a943f2acd4a6446c17a753131549a8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048548766"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9157073"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00180814", 
      "https://app.dimensions.ai/details/publication/pub.1048548766"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91444_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00180814"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00180814'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00180814'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00180814'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00180814'


 

This table displays all metadata directly associated to this object as RDF triples.

201 TRIPLES      21 PREDICATES      52 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00180814 schema:about N0ecd7c840adc494d801a05b64e57cc17
2 N30dacd22c1654631974594776c7776a1
3 N3e69dd378ab641019a390dd462952501
4 N561a9f9c058848e48e06396860fa2782
5 N58157fc3d9d54edd99221ad064e34bb1
6 N5fbb501b2d944136a6b7cdd6527e61b4
7 N75c2a02e23c94d4c8d37e52653329416
8 N77a942b0a0c14a70b659e99f2e0f17b3
9 N78a37e76e7f1454d86b2132530ef2e58
10 N91000a0bb11d475e9253ad248ef03ef0
11 Nd46d9f80db804602831b597a93191543
12 Nd599755724ad4519bbec5026eff03208
13 Nf9352a5ea4db4db8ad29f773e6d4997a
14 Nfd00672c25c44db195cc692d0d0658c0
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author Nb25d4427fa394a29859718b65e5efb47
18 schema:citation sg:pub.10.1007/s002800050524
19 https://doi.org/10.1002/bmc.1130070207
20 https://doi.org/10.1016/0010-468x(83)90006-5
21 https://doi.org/10.1016/0305-7372(93)90046-t
22 https://doi.org/10.1016/0378-4347(93)e0453-w
23 https://doi.org/10.1016/0378-4347(94)00481-j
24 https://doi.org/10.1016/0959-8049(95)00245-e
25 https://doi.org/10.1093/oxfordjournals.annonc.a058789
26 https://doi.org/10.1093/oxfordjournals.annonc.a059180
27 schema:datePublished 1996-12
28 schema:datePublishedReg 1996-12-01
29 schema:description We have conducted a clinical and pharmacokinetic trial of the novel podophyllotoxin derivative NK611 administered orally for 21 consecutive days. The treatment was repeated every 35 days. Eighteen patients were included into the study, all of whom were eligible. Due to early progression of tumor disease in two patients, 16 patients were evaluable for toxicity [7 female, 9 male, median age 64 years (range: 44 to 73)]. Dose escalation steps were 5 mg/day [105 mg per cycle (pc)], 10 mg/day (210 mg pc), 12.5 mg/day (265 mg pc) and 15 mg/day (315 mg pc). A total of 37 courses was administered. Toxicity was evaluated using NCI-CTC criteria. Granulocytopenia was the main hematologic toxicity. Other hematologic toxicities were sporadic. Non-hematologic toxicities were mild and consisted of grade 1 nausea and grade 2 alopecia. Pharmacokinetic analyses were performed in six patients each treated with 10 mg/day and 12.5 mg per day, and in one patient treated with 15 mg/day. Using a two-compartment model, t1/2 alpha ranged from 0.47 to 1.54 h and t1/2 beta from 2.0-11.6 h. Mean values for Cmax and AUC were 1.47 +/- 0.331 microgram/ml and 13.67 +/- 3.81 micrograms/ml.h. No objective tumor responses were observed. However, one patient with metastatic breast cancer had stable disease for twelve months. We conclude that the Maximum Tolerated Dose of NK611 administered daily for 21 consecutive days is 12.5 mg/day. The Dose-Limiting Toxicity is granulocytopenia. The recommended dose for further clinical Phase II studies is 10 mg/day.
30 schema:genre research_article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf Na0fac537b07e496cb17cefdc0208c2f7
34 Nce3086c674d74f759635bd709ee14e21
35 sg:journal.1094201
36 schema:name Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days
37 schema:pagination 379-386
38 schema:productId N387a63c0614544568c5e949950fadd2d
39 N541a755c8cb94ccab4a85ffddeff2564
40 Nc20ddd66dc2b4d73af595b23f4dd8dc3
41 Ne9372e96ee4241b78fef1c0b0edcb851
42 Nf9ef45b7ad8443288f3f36acb452c89d
43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048548766
44 https://doi.org/10.1007/bf00180814
45 schema:sdDatePublished 2019-04-15T09:01
46 schema:sdLicense https://scigraph.springernature.com/explorer/license/
47 schema:sdPublisher N1b8fe3d061aa4a3c87acf0d47b4f383c
48 schema:url http://link.springer.com/10.1007/BF00180814
49 sgo:license sg:explorer/license/
50 sgo:sdDataset articles
51 rdf:type schema:ScholarlyArticle
52 N00c7219380d547d8890b0230f732915e rdf:first sg:person.01215301435.50
53 rdf:rest Ncc354d26ce1240c3a7d4c983774ba490
54 N0ecd7c840adc494d801a05b64e57cc17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
55 schema:name Cell Count
56 rdf:type schema:DefinedTerm
57 N0f2796863a874161847233146e9d1019 rdf:first sg:person.0636044662.62
58 rdf:rest N3cc2e865b48b43efadc94762ee7b38dd
59 N1b8fe3d061aa4a3c87acf0d47b4f383c schema:name Springer Nature - SN SciGraph project
60 rdf:type schema:Organization
61 N30dacd22c1654631974594776c7776a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Administration, Oral
63 rdf:type schema:DefinedTerm
64 N387a63c0614544568c5e949950fadd2d schema:name nlm_unique_id
65 schema:value 8309330
66 rdf:type schema:PropertyValue
67 N3cc2e865b48b43efadc94762ee7b38dd rdf:first sg:person.0720105551.12
68 rdf:rest N00c7219380d547d8890b0230f732915e
69 N3e69dd378ab641019a390dd462952501 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Adult
71 rdf:type schema:DefinedTerm
72 N541a755c8cb94ccab4a85ffddeff2564 schema:name pubmed_id
73 schema:value 9157073
74 rdf:type schema:PropertyValue
75 N561a9f9c058848e48e06396860fa2782 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Neoplasms
77 rdf:type schema:DefinedTerm
78 N58157fc3d9d54edd99221ad064e34bb1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Neutropenia
80 rdf:type schema:DefinedTerm
81 N5fbb501b2d944136a6b7cdd6527e61b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Aged
83 rdf:type schema:DefinedTerm
84 N75c2a02e23c94d4c8d37e52653329416 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Humans
86 rdf:type schema:DefinedTerm
87 N77a942b0a0c14a70b659e99f2e0f17b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Middle Aged
89 rdf:type schema:DefinedTerm
90 N78a37e76e7f1454d86b2132530ef2e58 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Male
92 rdf:type schema:DefinedTerm
93 N85c8b75bec334865957655ddbe34d38d rdf:first sg:person.01032737635.01
94 rdf:rest N0f2796863a874161847233146e9d1019
95 N91000a0bb11d475e9253ad248ef03ef0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Antineoplastic Agents
97 rdf:type schema:DefinedTerm
98 Na0fac537b07e496cb17cefdc0208c2f7 schema:volumeNumber 14
99 rdf:type schema:PublicationVolume
100 Nb25d4427fa394a29859718b65e5efb47 rdf:first sg:person.0764624435.80
101 rdf:rest N85c8b75bec334865957655ddbe34d38d
102 Nc20ddd66dc2b4d73af595b23f4dd8dc3 schema:name readcube_id
103 schema:value e7472c7cc3d909221bbfe475fd1c97af62a943f2acd4a6446c17a753131549a8
104 rdf:type schema:PropertyValue
105 Ncc354d26ce1240c3a7d4c983774ba490 rdf:first sg:person.016016223701.26
106 rdf:rest Nf14b9f98e8874da3bf48067fb4d47e48
107 Nce3086c674d74f759635bd709ee14e21 schema:issueNumber 4
108 rdf:type schema:PublicationIssue
109 Nd46d9f80db804602831b597a93191543 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Female
111 rdf:type schema:DefinedTerm
112 Nd599755724ad4519bbec5026eff03208 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Leukopenia
114 rdf:type schema:DefinedTerm
115 Ne9372e96ee4241b78fef1c0b0edcb851 schema:name doi
116 schema:value 10.1007/bf00180814
117 rdf:type schema:PropertyValue
118 Nf14b9f98e8874da3bf48067fb4d47e48 rdf:first sg:person.01114224637.79
119 rdf:rest rdf:nil
120 Nf9352a5ea4db4db8ad29f773e6d4997a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Drug Administration Schedule
122 rdf:type schema:DefinedTerm
123 Nf9ef45b7ad8443288f3f36acb452c89d schema:name dimensions_id
124 schema:value pub.1048548766
125 rdf:type schema:PropertyValue
126 Nfd00672c25c44db195cc692d0d0658c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Podophyllotoxin
128 rdf:type schema:DefinedTerm
129 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
130 schema:name Medical and Health Sciences
131 rdf:type schema:DefinedTerm
132 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
133 schema:name Oncology and Carcinogenesis
134 rdf:type schema:DefinedTerm
135 sg:journal.1094201 schema:issn 0167-6997
136 1573-0646
137 schema:name Investigational New Drugs
138 rdf:type schema:Periodical
139 sg:person.01032737635.01 schema:affiliation https://www.grid.ac/institutes/grid.15474.33
140 schema:familyName Schrödel
141 schema:givenName H.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032737635.01
143 rdf:type schema:Person
144 sg:person.01114224637.79 schema:affiliation https://www.grid.ac/institutes/grid.15474.33
145 schema:familyName Hanauske
146 schema:givenName A. -R.
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114224637.79
148 rdf:type schema:Person
149 sg:person.01215301435.50 schema:affiliation https://www.grid.ac/institutes/grid.420017.0
150 schema:familyName Kaeser-Fröhlich
151 schema:givenName A.
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215301435.50
153 rdf:type schema:Person
154 sg:person.016016223701.26 schema:affiliation https://www.grid.ac/institutes/grid.15474.33
155 schema:familyName Rastetter
156 schema:givenName J.
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016016223701.26
158 rdf:type schema:Person
159 sg:person.0636044662.62 schema:affiliation https://www.grid.ac/institutes/grid.15474.33
160 schema:familyName Schilling
161 schema:givenName T.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636044662.62
163 rdf:type schema:Person
164 sg:person.0720105551.12 schema:affiliation https://www.grid.ac/institutes/grid.4527.4
165 schema:familyName Zucchetti
166 schema:givenName M.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720105551.12
168 rdf:type schema:Person
169 sg:person.0764624435.80 schema:affiliation https://www.grid.ac/institutes/grid.15474.33
170 schema:familyName Raßmann
171 schema:givenName I.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764624435.80
173 rdf:type schema:Person
174 sg:pub.10.1007/s002800050524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047341901
175 https://doi.org/10.1007/s002800050524
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1002/bmc.1130070207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029012041
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/0010-468x(83)90006-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048030318
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/0305-7372(93)90046-t schema:sameAs https://app.dimensions.ai/details/publication/pub.1039091038
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/0378-4347(93)e0453-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1033050826
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/0378-4347(94)00481-j schema:sameAs https://app.dimensions.ai/details/publication/pub.1047214758
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1016/0959-8049(95)00245-e schema:sameAs https://app.dimensions.ai/details/publication/pub.1016202311
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1093/oxfordjournals.annonc.a058789 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082692174
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1093/oxfordjournals.annonc.a059180 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082437870
192 rdf:type schema:CreativeWork
193 https://www.grid.ac/institutes/grid.15474.33 schema:alternateName Rechts der Isar Hospital
194 schema:name Division of Hematology and Oncology, Klinikum rechts der Isar der Technischen Universität München, München, Germany
195 rdf:type schema:Organization
196 https://www.grid.ac/institutes/grid.420017.0 schema:alternateName Evonik (Germany)
197 schema:name Asta Medica GmbH, Frankfurt, Germany
198 rdf:type schema:Organization
199 https://www.grid.ac/institutes/grid.4527.4 schema:alternateName Mario Negri Institute for Pharmacological Research
200 schema:name Oncological Department, Istituto “Mario Negri”, Milano, Italy
201 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...